5 results
In this study, plerixafor, the study drug, will be given in addition to GCSF to see if it works the same way in children as in adults.
Primary Objective: *To evaluate the immune responses 1 month after 3 doses of 13vPnC as measured by fold rises of serotype-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) in subjects *2 years of age. Secondary Objectives: *To…
The primary objective is to determine whether treatment of acute intermediate-risk PE (as defined by the inclusion and exclusion criteria) with parenteral anticoagulation for at least 72 hours after diagnosis, followed by dabigatran over 6 months,…
Primary objectiveTo determine the feasibility of plerixafor 320 *g/kg subcutaneously to harvest a sufficient number of CD34+ peripheral blood stem cells/kg recipient body weight. Feasibilty is defined as a minimum of 2.0x10^6/kg CD34+ cells in one…
Primary Safety Objective: To describe the safety profile of 20vPnC